Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.07
ALPMY's Cash to Debt is ranked lower than
52% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. ALPMY: 2.07 )
Ranked among companies with meaningful Cash to Debt only.
ALPMY' s 10-Year Cash to Debt Range
Min: 2.07  Med: 10000.00 Max: No Debt
Current: 2.07
Equity to Asset 0.75
ALPMY's Equity to Asset is ranked higher than
69% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. ALPMY: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
ALPMY' s 10-Year Equity to Asset Range
Min: 0.73  Med: 0.75 Max: 0.78
Current: 0.75
0.73
0.78
Interest Coverage 60.32
ALPMY's Interest Coverage is ranked lower than
63% of the 390 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2854.00 vs. ALPMY: 60.32 )
Ranked among companies with meaningful Interest Coverage only.
ALPMY' s 10-Year Interest Coverage Range
Min: 60.32  Med: 369.17 Max: 9999.99
Current: 60.32
60.32
9999.99
F-Score: 7
Z-Score: 7.40
M-Score: -2.42
WACC vs ROIC
5.93%
15.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 15.20
ALPMY's Operating margin (%) is ranked higher than
71% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.92 vs. ALPMY: 15.20 )
Ranked among companies with meaningful Operating margin (%) only.
ALPMY' s 10-Year Operating margin (%) Range
Min: 10.25  Med: 19.44 Max: 28.37
Current: 15.2
10.25
28.37
Net-margin (%) 11.16
ALPMY's Net-margin (%) is ranked higher than
69% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.96 vs. ALPMY: 11.16 )
Ranked among companies with meaningful Net-margin (%) only.
ALPMY' s 10-Year Net-margin (%) Range
Min: 7.09  Med: 11.32 Max: 18.24
Current: 11.16
7.09
18.24
ROE (%) 11.04
ALPMY's ROE (%) is ranked higher than
62% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.43 vs. ALPMY: 11.04 )
Ranked among companies with meaningful ROE (%) only.
ALPMY' s 10-Year ROE (%) Range
Min: 4.6  Med: 10.51 Max: 16.06
Current: 11.04
4.6
16.06
ROA (%) 8.26
ALPMY's ROA (%) is ranked higher than
70% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. ALPMY: 8.26 )
Ranked among companies with meaningful ROA (%) only.
ALPMY' s 10-Year ROA (%) Range
Min: 3.71  Med: 7.88 Max: 12.27
Current: 8.26
3.71
12.27
ROC (Joel Greenblatt) (%) 56.47
ALPMY's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.24 vs. ALPMY: 56.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALPMY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 26.38  Med: 60.29 Max: 84.28
Current: 56.47
26.38
84.28
Revenue Growth (3Y)(%) 10.40
ALPMY's Revenue Growth (3Y)(%) is ranked higher than
60% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. ALPMY: 10.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALPMY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -0.60 Max: 10.4
Current: 10.4
0
10.4
EBITDA Growth (3Y)(%) 11.90
ALPMY's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 494 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. ALPMY: 11.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALPMY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -11.90 Max: 11.9
Current: 11.9
0
11.9
EPS Growth (3Y)(%) 22.00
ALPMY's EPS Growth (3Y)(%) is ranked higher than
75% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ALPMY: 22.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALPMY' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 3.40 Max: 55.4
Current: 22
0
55.4
» ALPMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALPMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.50
ALPMY's P/E(ttm) is ranked higher than
59% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.60 vs. ALPMY: 27.50 )
Ranked among companies with meaningful P/E(ttm) only.
ALPMY' s 10-Year P/E(ttm) Range
Min: 7.26  Med: 15.93 Max: 53.2
Current: 27.5
7.26
53.2
PE(NRI) 27.50
ALPMY's PE(NRI) is ranked higher than
59% of the 478 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. ALPMY: 27.50 )
Ranked among companies with meaningful PE(NRI) only.
ALPMY' s 10-Year PE(NRI) Range
Min: 7.26  Med: 15.92 Max: 53.2
Current: 27.5
7.26
53.2
P/B 2.91
ALPMY's P/B is ranked higher than
51% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. ALPMY: 2.91 )
Ranked among companies with meaningful P/B only.
ALPMY' s 10-Year P/B Range
Min: 1.12  Med: 1.73 Max: 3.37
Current: 2.91
1.12
3.37
P/S 3.22
ALPMY's P/S is ranked lower than
52% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. ALPMY: 3.22 )
Ranked among companies with meaningful P/S only.
ALPMY' s 10-Year P/S Range
Min: 0.55  Med: 1.50 Max: 10.2
Current: 3.22
0.55
10.2
PFCF 56.11
ALPMY's PFCF is ranked lower than
61% of the 274 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.71 vs. ALPMY: 56.11 )
Ranked among companies with meaningful PFCF only.
ALPMY' s 10-Year PFCF Range
Min: 6.29  Med: 22.71 Max: 99.85
Current: 56.11
6.29
99.85
POCF 26.75
ALPMY's POCF is ranked higher than
51% of the 393 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.63 vs. ALPMY: 26.75 )
Ranked among companies with meaningful POCF only.
ALPMY' s 10-Year POCF Range
Min: 5  Med: 11.92 Max: 904.23
Current: 26.75
5
904.23
EV-to-EBIT 17.63
ALPMY's EV-to-EBIT is ranked higher than
64% of the 491 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.81 vs. ALPMY: 17.63 )
Ranked among companies with meaningful EV-to-EBIT only.
ALPMY' s 10-Year EV-to-EBIT Range
Min: 0.7  Med: 8.50 Max: 90.9
Current: 17.63
0.7
90.9
PEG 45.83
ALPMY's PEG is ranked lower than
94% of the 257 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. ALPMY: 45.83 )
Ranked among companies with meaningful PEG only.
ALPMY' s 10-Year PEG Range
Min: 0.63  Med: 1.21 Max: 2.06
Current: 45.83
0.63
2.06
Shiller P/E 29.92
ALPMY's Shiller P/E is ranked higher than
57% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.72 vs. ALPMY: 29.92 )
Ranked among companies with meaningful Shiller P/E only.
ALPMY' s 10-Year Shiller P/E Range
Min: 17.45  Med: 22.12 Max: 33.83
Current: 29.92
17.45
33.83
Current Ratio 2.44
ALPMY's Current Ratio is ranked higher than
53% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. ALPMY: 2.44 )
Ranked among companies with meaningful Current Ratio only.
ALPMY' s 10-Year Current Ratio Range
Min: 2.3  Med: 2.67 Max: 3.64
Current: 2.44
2.3
3.64
Quick Ratio 2.04
ALPMY's Quick Ratio is ranked higher than
58% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. ALPMY: 2.04 )
Ranked among companies with meaningful Quick Ratio only.
ALPMY' s 10-Year Quick Ratio Range
Min: 1.92  Med: 2.23 Max: 3.22
Current: 2.04
1.92
3.22
Days Inventory 161.28
ALPMY's Days Inventory is ranked lower than
71% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 111.99 vs. ALPMY: 161.28 )
Ranked among companies with meaningful Days Inventory only.
ALPMY' s 10-Year Days Inventory Range
Min: 89.8  Med: 135.87 Max: 160.01
Current: 161.28
89.8
160.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.67
ALPMY's Dividend Yield is ranked higher than
57% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.41 vs. ALPMY: 1.67 )
Ranked among companies with meaningful Dividend Yield only.
ALPMY' s 10-Year Dividend Yield Range
Min: 1.28  Med: 3.27 Max: 4.39
Current: 1.67
1.28
4.39
Dividend Payout 0.43
ALPMY's Dividend Payout is ranked lower than
63% of the 394 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. ALPMY: 0.43 )
Ranked among companies with meaningful Dividend Payout only.
ALPMY' s 10-Year Dividend Payout Range
Min: 0.68  Med: 1.26 Max: 16.19
Current: 0.43
0.68
16.19
Dividend growth (3y) 6.30
ALPMY's Dividend growth (3y) is ranked lower than
53% of the 255 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ALPMY: 6.30 )
Ranked among companies with meaningful Dividend growth (3y) only.
ALPMY' s 10-Year Dividend growth (3y) Range
Min: 1.3  Med: 6.30 Max: 52.5
Current: 6.3
1.3
52.5
Yield on cost (5-Year) 1.99
ALPMY's Yield on cost (5-Year) is ranked higher than
58% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.64 vs. ALPMY: 1.99 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALPMY' s 10-Year Yield on cost (5-Year) Range
Min: 1.51  Med: 3.87 Max: 5.19
Current: 1.99
1.51
5.19
Share Buyback Rate 1.50
ALPMY's Share Buyback Rate is ranked higher than
94% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.00 vs. ALPMY: 1.50 )
Ranked among companies with meaningful Share Buyback Rate only.
ALPMY' s 10-Year Share Buyback Rate Range
Min: 0  Med: 1.50 Max: -9.9
Current: 1.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 7.64
ALPMY's Price/Net Current Asset Value is ranked lower than
53% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. ALPMY: 7.64 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALPMY' s 10-Year Price/Net Current Asset Value Range
Min: 2.2  Med: 4.19 Max: 8.8
Current: 7.64
2.2
8.8
Price/Tangible Book 4.29
ALPMY's Price/Tangible Book is ranked lower than
54% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. ALPMY: 4.29 )
Ranked among companies with meaningful Price/Tangible Book only.
ALPMY' s 10-Year Price/Tangible Book Range
Min: 1.46  Med: 2.35 Max: 4.87
Current: 4.29
1.46
4.87
Price/Projected FCF 2.25
ALPMY's Price/Projected FCF is ranked higher than
56% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.70 vs. ALPMY: 2.25 )
Ranked among companies with meaningful Price/Projected FCF only.
ALPMY' s 10-Year Price/Projected FCF Range
Min: 0.27  Med: 1.72 Max: 4.66
Current: 2.25
0.27
4.66
Price/Median PS Value 2.15
ALPMY's Price/Median PS Value is ranked lower than
80% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. ALPMY: 2.15 )
Ranked among companies with meaningful Price/Median PS Value only.
ALPMY' s 10-Year Price/Median PS Value Range
Min: 0.37  Med: 1.00 Max: 6.33
Current: 2.15
0.37
6.33
Price/Peter Lynch Fair Value 1.21
ALPMY's Price/Peter Lynch Fair Value is ranked higher than
68% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.72 vs. ALPMY: 1.21 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALPMY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.42  Med: 0.87 Max: 1.68
Current: 1.21
0.42
1.68
Price/Graham Number 2.26
ALPMY's Price/Graham Number is ranked higher than
53% of the 360 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. ALPMY: 2.26 )
Ranked among companies with meaningful Price/Graham Number only.
ALPMY' s 10-Year Price/Graham Number Range
Min: 0.85  Med: 1.57 Max: 2.62
Current: 2.26
0.85
2.62
Earnings Yield (Greenblatt) (%) 5.70
ALPMY's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. ALPMY: 5.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALPMY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.1  Med: 11.70 Max: 145.1
Current: 5.7
1.1
145.1
Forward Rate of Return (Yacktman) (%) 24.97
ALPMY's Forward Rate of Return (Yacktman) (%) is ranked higher than
82% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.88 vs. ALPMY: 24.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALPMY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 4.6  Med: 24.80 Max: 26
Current: 24.97
4.6
26

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:4503.Japan, YPH.Germany,
Astellas Pharma Inc was incorporated on March 20, 1939. The Company and its subsidiaries are engaged in the manufacturing, marketing of pharmaceuticals products. It develops products in the areas of urology, immunology and allergy, cardiovascular, diabetes, gastrointestinal and motor organs. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis in the topical immunomodulator class; Vesicare, a treatment for overactive bladder; Harnal, an a1 blocking agent for the treatment of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The Company's products also comprise Geninax, an oral quinolone antibacterial agent; Celecox, a selective COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, an antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. The Company also offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI.
» More Articles for ALPMY

Headlines

Articles On GuruFocus.com
Charles de Vaulx Sells Portions of Three of His Most Valuable Stakes Jun 01 2015 
IVA International Fund Q1 2015 Review May 28 2015 
Charles de Vaulx’s IVA Worldwide Fund Q1 2015 Review May 28 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
IVA International Fund Q4 2014 Review Mar 31 2015 
IVA International Fund 2014 Annual Commentary Jan 02 2015 
IVA Worldwide Fund 2014 Annual Commentary Jan 02 2015 
A Look at Global Investor Charles De Vaulx's Top 5 Holdings Dec 02 2014 
IVA International Fund Q3 2014 Review Oct 29 2014 

More From Other Websites
Astellas Pharma Inc. -- Moody's: Japan's increasing use of generics will pressure pharmaceutical... Aug 25 2015
AVEO Pharmaceuticals Posts Narrower-than-Expected Loss - Analyst Blog Aug 11 2015
Medivation Tops Q2 Earnings & Ups View, Xtandi Impresses - Analyst Blog Aug 07 2015
Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award Jun 04 2015
New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of... Jun 01 2015
Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In... May 30 2015
Astellas' Myrbetriq for Overactive Bladder Efficient as Add-On - Analyst Blog May 18 2015
Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin... May 17 2015
Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological... May 17 2015
Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and... May 14 2015
Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual... May 05 2015
Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology... Apr 21 2015
Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog Apr 08 2015
Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog Apr 06 2015
Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function Apr 06 2015
MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute... Apr 03 2015
Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival... Apr 02 2015
Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog Mar 26 2015
Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog Mar 26 2015
Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the... Mar 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK